Ciancetta Antonella, Jacobson Kenneth A
Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD, 20892, USA.
Methods Mol Biol. 2018;1705:45-72. doi: 10.1007/978-1-4939-7465-8_3.
Recent crystallographic structures of G protein-coupled receptors (GPCRs) have greatly advanced our understanding of the recognition of their diverse agonist and antagonist ligands. We illustrate here how this applies to A adenosine receptors (ARs) and to P2Y and P2Y receptors (P2YRs) for ADP. These X-ray structures have impacted the medicinal chemistry aimed at discovering new ligands for these two receptor families, including receptors that have not yet been crystallized but are closely related to the known structures. In this Chapter, we discuss recent structure-based drug design projects that led to the discovery of: (a) novel AAR agonists based on a highly rigidified (N)-methanocarba scaffold for the treatment of chronic neuropathic pain and other conditions, (b) fluorescent probes of the ARs and P2YR, as chemical tools for structural probing of these GPCRs and for improving assay capabilities, and (c) new more drug-like antagonists of the inflammation-related P2YR. We also describe the computationally enabled molecular recognition of positive (for AAR) and negative (P2YR) allosteric modulators that in some cases are shown to be consistent with structure-activity relationship (SAR) data. Thus, computational modeling has become an essential tool for the design of purine receptor ligands.
G蛋白偶联受体(GPCRs)的最新晶体结构极大地推动了我们对其多种激动剂和拮抗剂配体识别的理解。我们在此说明这如何应用于A类腺苷受体(ARs)以及针对二磷酸腺苷(ADP)的P2Y和P2Y受体(P2YRs)。这些X射线结构影响了旨在为这两个受体家族发现新配体的药物化学研究,包括那些尚未结晶但与已知结构密切相关的受体。在本章中,我们讨论了最近基于结构的药物设计项目,这些项目导致发现了:(a)基于高度刚性化的(N)-甲碳环支架的新型AAR激动剂,用于治疗慢性神经性疼痛和其他病症;(b)ARs和P2YR的荧光探针,作为用于这些GPCRs结构探测和改善检测能力的化学工具;(c)与炎症相关的P2YR的新型更具药物特性的拮抗剂。我们还描述了对正性(针对AAR)和负性(P2YR)变构调节剂的计算辅助分子识别,在某些情况下,这些识别结果与构效关系(SAR)数据一致。因此,计算建模已成为嘌呤受体配体设计的重要工具。